Whereas clinical trials on PD1-based immune checkpoint inhibition have shown great anti-tumor efficacy in dMMR (MSI-high) CRC, pMMR (MSI-low or microsatellite stable [MSS]) tumors that occur in the majority of CRC and CRLM patients do not respond well to ICB.6 The gene discussed is PDCD1; the disease is colorectal carcinoma.